Page updated ·next FDA decision on the calendar·Data as of Nov 5, 2026 9:00 PM ET
Price into the decision (T-120)
Daily close, T-120 (8/20/24) through T+5. Run-up high $39.41 on 1/27/25, low $29.94 on 10/2/24 (T-120 to T-1). FDA decision 2/4/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 21, 2025, 14 days before the decision date, at-the-money options priced a move of ±12.3% through Feb 21, 2025 (the first listed expiry after the decision; ATM implied volatility 52%). The stock closed +7.1% at the first close across the decision and +1.5% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.
Questions
Was ONAPGO (apomorphine hydrochloride) injection (SPN-830) approved by the FDA?
Yes. The FDA approved the application for ONAPGO (apomorphine hydrochloride) injection (SPN-830) on February 3, 2025, per the FDA's own record. The company announced it on February 4, 2025. The primary source is linked on this page.
What was ONAPGO (apomorphine hydrochloride) injection (SPN-830) under FDA review for?
The application covered Motor fluctuations in Parkinson’s disease (PD). The FDA approved the application on February 4, 2025.
How did SUPN stock react to the FDA decision?
On the decision day SUPN moved +7.1%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.